Two Sigma Advisers’s Lantern Pharma LTRN Stock Holding History

Two Sigma Advisers’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,300	Closed	-$202K	–	2830
2021 Q4	$202K	Buy	+25,300	New	+$231K	﹤0.01%	2286

Other funds holding LTRN

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

WWM

Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Two Sigma Advisers's LTRN Position: Q1 2022 in Review

Two Sigma Advisers sold out of Lantern Pharma (LTRN) in Q1 2022, closing a stake of 25,300 shares — an estimated $202K sold.

Two Sigma Advisers first reported a position in LTRN in Q4 2021 and held it in 1 quarter. The position peaked at $202K in Q4 2021. 25 funds tracked by Wall St. Rank hold LTRN as of Q1 2022.

Two Sigma Advisers reported no remaining Lantern Pharma position as of Q1 2022 after selling out during the quarter.
Two Sigma Advisers sold 25,300 Lantern Pharma shares in Q1 2022, an estimated $202K.
Two Sigma Advisers first reported a position in Lantern Pharma in Q4 2021 and held it in 1 quarter.
Two Sigma Advisers's Lantern Pharma position peaked at $202K in Q4 2021.
25 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2022.

Based on Two Sigma Advisers's 13F filing for Q1 2022, filed 16 May 2022.